Search hospitals > Washington > Seattle
Virginia Mason Medical Center
Claim this profileSeattle, Washington 98101
Global Leader in Skin Cancer
Global Leader in Prostate Cancer
Conducts research for Breast Cancer
Conducts research for Stomach Cancer
Conducts research for Pancreatic Cancer
506 reported clinical trials
25 medical researchers
Summary
Virginia Mason Medical Center is a medical facility located in Seattle, Washington. This center is recognized for care of Skin Cancer, Prostate Cancer, Breast Cancer, Stomach Cancer, Pancreatic Cancer and other specialties. Virginia Mason Medical Center is involved with conducting 506 clinical trials across 639 conditions. There are 25 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Vincent Picozzi, MD, and Hagen F. Kennecke.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Prostate Cancer
Global LeaderStage IV
PD-L1 positive
Stage II
Top PIs
Huong T. PhamVirginia Mason Medical Center1 year of reported clinical research
Studies Colorectal Cancer
Studies Lung Cancer
22 reported clinical trials
55 drugs studied
David Aboulafia, MDVirginia Mason Medical Center9 years of reported clinical research
Studies Lymphoma
Studies Soft Tissue Sarcoma
12 reported clinical trials
27 drugs studied
Vincent Picozzi, MDVirginia Mason Medical Center5 years of reported clinical research
Studies Pancreatic Cancer
Studies Pancreatic Adenocarcinoma
6 reported clinical trials
17 drugs studied
Hagen F. KenneckeVirginia mason medical Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Rectal Cancer
6 reported clinical trials
17 drugs studied
Clinical Trials running at Virginia Mason Medical Center
Bladder Cancer
Pancreatic Cancer
Lung Cancer
Stomach Cancer
Hearing Loss
Rectal Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Prostate Cancer
Gemcitabine + Docetaxel vs BCG
for Bladder Cancer
This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.
Recruiting2 awards Phase 314 criteria
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Mason Medical Center?
Virginia Mason Medical Center is a medical facility located in Seattle, Washington. This center is recognized for care of Skin Cancer, Prostate Cancer, Breast Cancer, Stomach Cancer, Pancreatic Cancer and other specialties. Virginia Mason Medical Center is involved with conducting 506 clinical trials across 639 conditions. There are 25 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Vincent Picozzi, MD, and Hagen F. Kennecke.
Where is Virginia Mason Medical Center located?
Virginia Mason Medical Center is located at 1100 9th Ave, Seattle, WA 98101. It is accessible by public transportation, with Metro bus line number 2 stopping on Seneca St.
Who should I call to ask about financial aid or insurance network?
**Virginia Mason Medical Center Contact Information**
**Financial Assistance:**
- For assistance, please refer to the Financial Assistance Application form or call the main hospital number.
**Insurance:**
- Billing Office Contact: 206-223-6601 or 1-800-553-xxxx (Available Monday through Friday, 8 a.m. to 5 p.m.)
- For specific questions regarding care, insurance coverage, or billing, contact your provider directly or use the Patient Cost Estimator for out-of-pocket cost estimates.
What insurance does Virginia Mason Medical Center accept?
Virginia Mason Medical Center accepts a broad spectrum of insurance plans, including but not limited to PacificSource Medicare Advantage, Premera PersonalCare, Regence Accountable Health Networks, and UnitedHealthcare. Coverage extends to a variety of plans such as Aetna, Amerigroup, Apple Health, CIGNA, and Medicare among others. Patients are advised to verify with their insurance provider for the most current coverage information.
What awards or recognition has Virginia Mason Medical Center received?
**Virginia Mason Medical Center, Seattle, Washington**
- Recognized as a Top Teaching Hospital nationally by The Leapfrog Group.
- Achievements in patient safety and quality.
- Ranked among the top 5% of eligible hospitals in the nation, emphasizing their commitment to high-quality care and excellence in training future medical professionals.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.